James Strauss

1.3k total citations · 1 hit paper
69 papers, 837 citations indexed

About

James Strauss is a scholar working on Oncology, Immunology and Biotechnology. According to data from OpenAlex, James Strauss has authored 69 papers receiving a total of 837 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 24 papers in Immunology and 13 papers in Biotechnology. Recurrent topics in James Strauss's work include Cancer Immunotherapy and Biomarkers (23 papers), Cancer Research and Treatments (13 papers) and Immunotherapy and Immune Responses (10 papers). James Strauss is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Cancer Research and Treatments (13 papers) and Immunotherapy and Immune Responses (10 papers). James Strauss collaborates with scholars based in United States, United Kingdom and Canada. James Strauss's co-authors include Joshua Brody, Anuradha Khilnani, Kevin J. Harrington, Talia Golan, Aurélien Marabelle, Archie Tse, Sašo Čemerski, Eugene P. Frenkel, Barbara M. Osborne and Rodger L. Bick and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

James Strauss

66 papers receiving 817 citations

Hit Papers

Phase I Study of SYNB1891, an Engineered E. coli Nissle S... 2023 2026 2024 2025 2023 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
    2023 84 citations Jason J. Luke, Sarina A. Piha‐Paul et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Strauss United States 14 394 370 224 103 92 69 837
Chang Gon Kim South Korea 11 470 1.2× 364 1.0× 282 1.3× 90 0.9× 60 0.7× 15 893
Amer Assal United States 10 591 1.5× 433 1.2× 203 0.9× 81 0.8× 35 0.4× 32 941
James M. Leatherman United States 13 461 1.2× 443 1.2× 271 1.2× 39 0.4× 33 0.4× 26 814
Heng Lin China 11 566 1.4× 374 1.0× 250 1.1× 37 0.4× 88 1.0× 26 944
Shotaro Iwamoto Japan 15 508 1.3× 680 1.8× 266 1.2× 45 0.4× 45 0.5× 65 1.2k
Michael Fehlings Singapore 10 370 0.9× 442 1.2× 217 1.0× 26 0.3× 134 1.5× 21 756
Keyuan Chen China 8 425 1.1× 448 1.2× 326 1.5× 57 0.6× 32 0.3× 17 821
Debora Martorelli Italy 20 564 1.4× 369 1.0× 186 0.8× 48 0.5× 92 1.0× 34 989
Jens Schreiner Germany 15 649 1.6× 535 1.4× 204 0.9× 146 1.4× 53 0.6× 22 1.2k
Wilhem Leconet France 11 232 0.6× 178 0.5× 141 0.6× 64 0.6× 78 0.8× 12 514

Countries citing papers authored by James Strauss

Since Specialization
Citations

This map shows the geographic impact of James Strauss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Strauss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Strauss more than expected).

Fields of papers citing papers by James Strauss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Strauss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Strauss. The network helps show where James Strauss may publish in the future.

Co-authorship network of co-authors of James Strauss

This figure shows the co-authorship network connecting the top 25 collaborators of James Strauss. A scholar is included among the top collaborators of James Strauss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Strauss. James Strauss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harrington, Kevin J., Stéphane Champiat, Joshua Brody, et al.. (2025). Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 31(16). 3400–3411. 10 indexed citations
2.
Vaishampayan, Ulka N., Jameel Muzaffar, Ira Winer, et al.. (2024). Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1). Journal for ImmunoTherapy of Cancer. 12(11). e010143–e010143. 14 indexed citations
3.
Pant, Shubham, Erika Hamilton, Susanna V. Ulahannan, et al.. (2023). Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors. Cancer. 129(12). 1919–1929. 4 indexed citations
4.
Luke, Jason J., Sarina A. Piha‐Paul, Theresa Medina, et al.. (2023). Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clinical Cancer Research. 29(13). 2435–2444. 84 indexed citations breakdown →
5.
Tolcher, Anthony W., Michael S. Gordon, Kathleen M. Mahoney, et al.. (2023). Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 11(2). e005267–e005267. 22 indexed citations
6.
Någård, Mats, Mei-Lin Ah-See, James Strauss, et al.. (2023). Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 92(3). 193–203. 1 indexed citations
7.
Hayenga, Heather N., Chunyu Cai, David T. Fetzer, et al.. (2022). Rare solid and cystic presentation of hemangiopericytoma/ solitary fibrous tumor: A case report. SHILAP Revista de lepidopterología. 6. 100149–100149. 1 indexed citations
8.
Patnaik, Amita, Inderjit Mehmi, James Strauss, et al.. (2021). 135P First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors. Annals of Oncology. 32. S1435–S1436. 6 indexed citations
9.
Barve, Minal, Ming‐Shiang Wu, Kathleen F. Pirollo, et al.. (2021). A phase II trial combining tumor-targeting TP53 gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer.. Journal of Clinical Oncology. 39(15_suppl). 4139–4139. 11 indexed citations
10.
11.
Strauss, James, et al.. (2020). 71MO OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial. Annals of Oncology. 31. S1270–S1270. 2 indexed citations
12.
Bitterman, Danielle S., Kathryn Winter, Theodore S. Hong, et al.. (2020). Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. International Journal of Radiation Oncology*Biology*Physics. 109(1). 201–211. 5 indexed citations
13.
14.
Byers, Lauren A., Kathryn A. Gold, Julio A. Peguero, et al.. (2018). P2.13-10 Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC. Journal of Thoracic Oncology. 13(10). S801–S802. 1 indexed citations
15.
16.
17.
Bick, Rodger L., James Strauss, & Eugene P. Frenkel. (1996). THROMBOSIS AND HEMORRHAGE IN ONCOLOGY PATIENTS. Hematology/Oncology Clinics of North America. 10(4). 875–908. 43 indexed citations
18.
Osborne, Barbara M., et al.. (1995). Follicular Lymphoma Adjacent to Foreign Body Granulomatous Inflammation and Fibrosis Surrounding Silicone Breast Prosthesis. The American Journal of Surgical Pathology. 19(6). 712–717. 69 indexed citations
19.
Bick, Rodger L. & James Strauss. (1995). Thrombolytic Therapy and Its Uses. Laboratory Medicine. 26(5). 330–337. 1 indexed citations
20.
Strauss, James, et al.. (1993). Resection of a solid and papillary epithelial neoplasm of the pancreas following treatment with Cis‐platinum and 5‐fluorouracil: A case report. Medical and Pediatric Oncology. 21(5). 365–367. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chang Gon Kim Breakdown of academic impact, for papers by Amer Assal Breakdown of academic impact, for papers by James M. Leatherman Breakdown of academic impact, for papers by Heng Lin Breakdown of academic impact, for papers by Shotaro Iwamoto Breakdown of academic impact, for papers by Michael Fehlings Breakdown of academic impact, for papers by Keyuan Chen Breakdown of academic impact, for papers by Debora Martorelli Breakdown of academic impact, for papers by Jens Schreiner Breakdown of academic impact, for papers by Wilhem Leconet
Rankless by CCL
2026